First environmental isolation of Cryptococcus gattii, genotype AFLP5, from India and a global review

Mycoses

Volumn 56, Issue 3, 2013, Pages 222-228

  Chowdhary, A ^a   Prakash, A ^a   Randhawa, H S ^a   Kathuria, S ^a   Hagen, F ^b   Klaassen, C H ^b   Meis, J F ^b,c  

^a UNIVERSITY OF DELHI   (India)

^b CANISIUS WILHELMINA HOSPITAL   (Netherlands)

^c RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Antifungal agents; Cryptococcus gattii genotype AFLP5 VGIII; Environment; India; Isavuconazole; Multi locus sequence typing

Indexed keywords

ISAVUCONAZOLE; POSACONAZOLE;

AMPLIFIED FRAGMENT LENGTH POLYMORPHISM; ANTIFUNGAL SUSCEPTIBILITY; COLOMBIA; CONCENTRATION RESPONSE; CRYPTOCOCCUS GATTII; FUNGAL GENETICS; FUNGUS ISOLATION; GENOTYPE; IN VITRO STUDY; INDIA; MANILKARA; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PHYLOGENY; PRIORITY JOURNAL; REVIEW; UNITED STATES; WOOD;

AMPHOTERICIN B; AMPLIFIED FRAGMENT LENGTH POLYMORPHISM ANALYSIS; ANTIFUNGAL AGENTS; CRYPTOCOCCUS GATTII; DNA, FUNGAL; GENOTYPE; HUMANS; INDIA; MANILKARA; MICROBIAL SENSITIVITY TESTS; PHYLOGENY; PLANT DISEASES; SOIL MICROBIOLOGY;

CRYPTOCOCCUS GATTII; FUNGI; MANILKARA HEXANDRA;

EID: 84876299820     PISSN: 09337407     EISSN: 14390507     Source Type: Journal    
DOI: 10.1111/myc.12039     Document Type: Review

References (43)

1. Speed B, Dunt D. Clinical and host differences between infections with the two varieties of Cryptococcus neoformans. Clin Infect Dis 1995; 21: 28-34.
2. Springer DJ, Chaturvedi V. Projecting global occurrence of Cryptococcus gattii. Emerg Infect Dis 2010; 16: 14-20.
3. Kidd SE, Chow Y, Mak S et al. Characterization of environmental sources of the human and animal pathogen, Cryptococcus gattii, in British Columbia, Canada, and the Pacific Northwest of the United States. Appl Environ Microbiol 2007; 73: 1433-43.
4. Mitchell TG, Castañeda E, Nielson K, Wanke B, Lazera MS. Environmental niches for Cryptococcus neoformans and Cryptococcus gattii. In: Heitman J, Kozel TR, Kwon-Chung KJ, Perfect JR, Casadevall A (eds), Cryptococcus: From Human Pathogen to Model Yeast. Washington, DC: ASM Press, 2011: 237-59.
5. Chowdhary A, Randhawa HS, Boekhout T et al. Temperate climate niche for Cryptococcus gattii in Northern Europe. Emerg Infect Dis 2012; 18: 172-4.
6. Litvintseva AP, Thakur R, Reller LB, Mitchell TG. Prevalence of clinical isolates of Cryptococcus gattii serotype C among patients with AIDS in Sub-Saharan Africa. J Infect Dis 2005; 192: 888-92.
7. Byrnes EJ 3rd, Li W, Ren P et al. A diverse population of Cryptococcus gattii molecular type VGIII in southern Californian HIV/AIDS patients. PLoS Pathog 2011; 7: e1002205.
8. Olivares LR, Martínez KM, Cruz RM et al. Genotyping of Mexican Cryptococcus neoformans and C. gattii isolates by PCR-fingerprinting. Med Mycol 2009; 47: 713-21.
9. Trilles L, Lazéra Mdos S, Wanke B et al. Regional pattern of the molecular types of Cryptococcus neoformans and Cryptococcus gattii in Brazil. Mem Inst Oswaldo Cruz 2008; 103: 455-62.
10. Souza LK, Souza AH Jr, Costa CR et al. Molecular typing and antifungal susceptibility of clinical and environmental Cryptococcus neoformans species complex isolates in Goiania, Brazil. Mycoses 2010; 53: 62-7.
11. Escandón P, Sánchez A, Firacative C, Castañeda E. Isolation of Cryptococcus gattii molecular type VGIII, from Corymbia ficifolia detrius in Colombia. Med Mycol 2010; 48: 657-8.
12. Firacative C, Torres G, Rodríguez MC, Escandón P. First isolation of Cryptococcus gattii serotype B, from Cúcuta, Colombia. Biomédica 2011; 31: 118-23.
13. Hagen F, Illnait-Zaragozi MT, Bartlett KH et al. In vitro antifungal susceptibilities and AFLP genotyping of a worldwide collection of 350 clinical, veterinary and environmental Cryptococcus gattii isolates. Antimicrob Agents Chemother 2010; 54: 5139-45.
14. Randhawa HS, Kowshik T, Sinha KP et al. Distribution of Cryptococcus gattii and Cryptococcus neoformans in decayed trunk wood of Syzygium cumini trees in north-western India. Med Mycol 2006; 44: 623-30.
15. Randhawa HS, Kowshik T, Chowdhary A et al. The expanding host tree species spectrum of Cryptococcus gattii and Cryptococcus neoformans and their isolations from surrounding soil in India. Med Mycol 2008; 46: 823-33.
16. Hiremath SS, Chowdhary A, Randhawa HS et al. Long distance dispersal and recombination in environmental populations of Cryptococcus neoformans var. grubii from India. Microbiology 2008; 154: 1513-24.
17. Chowdhary A, Hiremath SS, Sun S et al. Genetic differentiation and clonal expansion of environmental populations of Cryptococcus gattii in India. Environ Microbiol 2011; 13: 1875-88.
18. Chowdhary A, Randhawa HS, Prakash A, Meis JF. Environmental prevalence of Cryptococcus neoformans and C. gattii in India: an update. Crit Rev Microbiol 2012; 38: 1-16.
19. Boekhout T, Theelen B, Diaz M et al. Hybrid genotypes in the pathogenic yeast Cryptococcus neoformans. Microbiology 2001; 147: 891-907.
20. Meyer W, Gilgado F, Ngamskulrungroj P, et al. Molecular typing of the Cryptococcus neoformans/Cryptococcus gattii species complex. In: Heitman J, Kozel TR, Kwon-Chung KJ, Perfect JR, Casadevall A (eds), Cryptococcus: From Human Pathogen to Model Yeast. Washington, DC: ASM Press, 2011: 327-57.
21. Hagen F, Colom MF, Swinne D et al. Autochthonous and dormant Cryptococcus gattii infections in Europe. Emerg Infect Dis 2012; 18: 1618-24.
22. Fraser JA, Giles SS, Wenink EC et al. Same-sex mating and the origin of the Vancouver Island Cryptococcus gattii outbreak. Nature 2005; 437: 1360-4.
23. Tamura K, Peterson D, Peterson N et al. MEGA5: molecular evolutionary genetics analysis using maximum likelihood, evolutionary distance, and maximum parsimony methods. Mol Biol Evol 2011; 28: 2731-9.
24. CLSI (2008). Reference Method for Broth Dilution Antifungal Susceptibility Testing of Yeasts, 3rd edn. Approved standard, M27-A3. Wayne, PA: Clinical and Laboratory Standards Institute.
25. Espinel-Ingroff A, Aller AI, Canton E et al. Cryptococcus neoformans-Cryptococcus gattii species complex: an international study of wild-type susceptibility endpoint distributions and epidemiological cutoff values for fluconazole, itraconazole, posaconazole and voriconazole. Antimicrob Agents Chemother 2012; 56: 5898-906.
26. Espinel-Ingroff A, Chowdhary A, Cuenca-Estrella M et al. Wild-type susceptibility endpoint distributions and epidemiological cutoff values for amphotericin B and flucytosine versus Cryptococcus neoformans-Cryptococcus gattii species complex: an international study. Antimicrob Agents Chemother 2012; 56: 3107-13.
27. Sorrell TC, Chen SC, Ruma P et al. Concordance of clinical and environmental isolates of Cryptococcus neoformans var. gattii by random amplification of polymorphic DNA analysis and PCR fingerprinting. J Clin Microbiol 1996; 34: 1253-60.
28. Iqbal N, Debess EE, Wohrle R et al. Correlation of genotype and in vitro susceptibilities of Cryptococcus gattii from the Pacific Northwest of the United States. J Clin Microbiol 2009; 48: 539-44.
29. Walraven CJ, Gerstein W, Hardison SE et al. Fatal disseminated Cryptococcus gattii infection in New Mexico. PLoS ONE 2011; 6: e28625.
30. Katsu M, Kidd S, Ando A et al. The internal transcribed spacers and 5.8S rRNA gene show extensive diversity among isolates of Cryptococcus neoformans species complex. FEMS Yeast Res 2004; 4: 377-88.
31. Escandón P, Sánchez A, Martínez M, Meyer W, Castañeda E. Molecular epidemiology of clinical and environmental isolates of the Cryptococcus neoformans species complex reveals a high genetic diversity and the presence of the molecular type VGII mating type a in Colombia. FEMS Yeast Res 2006; 6: 625-35.
32. Trilles L, Lazera M, Wanke B, Theelen B, Boekhout T. Genetic characterization of environmental isolates of the Cryptococcus neoformans species complex from Brazil. Med Mycol 2003; 41: 383-90.
33. Campbell LT, Fraser JA, Nichols CB et al. Clinical and environmental isolates of Cryptococcus gattii from Australia that retain sexual fecundity. Eukaryot Cell 2005; 4: 1410-9.
34. Lemmer K, Naumann D, Raddatz B, Tintelnot K. Molecular typing of Cryptococcus neoformans by PCR fingerprinting, in comparison with serotyping and Fourier transform infrared-spectroscopy-based phenotyping. Med Mycol 2004; 42: 135-47.
35. Padhye AA, Chakrabarti A, Chander J, Kaufman L. Cryptococcus neoformans var. gattii in India. J Med Vet Mycol 1993; 31: 165-8.
36. Abraham M, Mathews V, Ganesh A, John TJ, Mathews MS. Infection caused by Cryptococcus neoformans var. gattii, serotype B in an AIDS patient in India. J Med Vet Mycol 1997; 35: 283-4.
37. Peerapur BV, Mantur BG, Smita S, Mangalagi SS, Birdar MS. Infection caused by Cryptococcus neoformans var. gattii serotype B in an AIDS patient in Bijapur. Indian J Med Microbiol 2000; 18: 45.
38. Khyriem AB, Sujatha S, Parija SC. Chronic meningitis in an immunocompetent adult caused by Cryptococcus neoformans var. gattii. Indian J Med Microbiol 2004; 22: 275.
39. Banerjee U, Dutta K, Casadevall A. Serotype distribution of Cryptococcus neoformans in patients in a tertiary care centre in India. Med Mycol 2004; 42: 181-6.
40. Cogliati M, Chandrashekar N, Esposto MC et al. Cryptococcus gattii serotype-C strains isolated in Bangalore, Karnataka, India. Mycoses 2012; 55: 262-8.
41. Ellis D, Marriott D, Hajjeh RA et al. Epidemiology: surveillance of fungal infections. Med Mycol 2000; 38: 173-82.
42. Jain N, Wickes BL, Keller SM et al. Molecular epidemiology of clinical Cryptococcus neoformans strains in India. J Clin Microbiol 2005; 43: 5733-42.
43. Chowdhary A, Randhawa HS, Sundar G et al. In vitro antifungal susceptibility profiles and genotypes of 308 clinical and environmental isolates of Cryptococcus var. grubii and Cryptococcus gattii serotype B from north-western India. J Med Microbiol 2011; 60: 961-7.